Current
interpretation for EVAR Trial 2
EVAR had a considerable 30 day operative mortality in patients already unfit
for open repair of their aneurysm. EVAR did not improve longer-term survival
and was associated with a need for continued surveillance and re-interventions,
at substantially increased cost. Thus, in these sick patients the emphasis
has shifted towards improving patient fitness before considering EVAR, particularly
in terms of cardiac, respiratory and renal function. Ongoing follow-up of
these patients is an important priority.
